BerGenBio investor relations material

Listen to the latest call from BerGenBio

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. BerGenBio has also initiated its early stage development programs on epacadostat and devicine.

Dig deeper into the BerGenBio fundamentals on Quartr.